Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1350 of 2228 entries
View as:

Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01374802 Org: User:
Start: 06/30/11 End: - Due: -

Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02256774 Org: User:
Start: 10/31/04 End: - Due: -

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

Phase: N/A Priority: Normal
NCT ID: NCT06166992 Org: User:
Start: 12/12/23 End: 02/07/24 Due: 02/07/25

Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02183675 Org: User:
Start: 07/31/14 End: 10/31/14 Due: 10/31/15

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

Phase: N/A Priority: Normal
NCT ID: NCT00772538 Org: User:
Start: 10/31/08 End: - Due: -

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIBN 4096 BS in Healthy Male and Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02194335 Org: User:
Start: 10/31/00 End: - Due: -

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

Phase: N/A Priority: Normal
NCT ID: NCT03448406 Org: User:
Start: 03/20/18 End: 10/09/19 Due: 10/09/20

This Study in Healthy Volunteers Determines the Amount of BI 730460 in the Blood When Taken as Tablet. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.

Phase: N/A Priority: Normal
NCT ID: NCT03483077 Org: User:
Start: 10/09/18 End: 03/21/19 Due: 03/21/20

Telmisartan in Mild to Moderate Hypertensive Patients

Phase: N/A Priority: Normal
NCT ID: NCT02260089 Org: User:
Start: 03/31/00 End: - Due: -

Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02183428 Org: User:
Start: 05/31/08 End: - Due: -

A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)

Phase: N/A Priority: Normal
NCT ID: NCT06962852 Org: User:
Start: 05/20/25 End: 09/18/47 Due: 09/18/48

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05839600 Org: User:
Start: 06/07/23 End: 04/10/25 Due: 04/10/26

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Phase: N/A Priority: Normal
NCT ID: NCT05211947 Org: User:
Start: 03/21/22 End: 03/18/25 Due: 03/18/26

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

Phase: N/A Priority: Normal
NCT ID: NCT04752215 Org: User:
Start: 05/18/21 End: 11/19/24 Due: 11/19/25

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

Phase: N/A Priority: Normal
NCT ID: NCT06393127 Org: User:
Start: 06/04/24 End: 09/13/24 Due: 09/13/25

Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01950273 Org: User:
Start: 09/27/13 End: 12/22/15 Due: 12/22/16

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

Phase: N/A Priority: Normal
NCT ID: NCT06081530 Org: User:
Start: 10/27/23 End: 03/20/25 Due: 03/20/26

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT05376800 Org: User:
Start: 11/07/22 End: 08/29/25 Due: 08/29/26

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05963867 Org: User:
Start: 08/06/24 End: 07/25/26 Due: 07/25/27

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04978493 Org: User:
Start: 12/02/21 End: 08/08/24 Due: 08/08/25

Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Population

Phase: N/A Priority: Normal
NCT ID: NCT00614302 Org: User:
Start: 06/30/07 End: - Due: -

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01177813 Org: User:
Start: 07/31/10 End: - Due: -

Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT02242240 Org: User:
Start: 03/31/01 End: - Due: -

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06077500 Org: User:
Start: 02/14/24 End: 06/25/26 Due: 06/25/27

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Phase: N/A Priority: Normal
NCT ID: NCT05327946 Org: User:
Start: 05/17/22 End: 09/30/26 Due: 09/30/27